Due to its Schedule I drug designation, medical cannabis continues to remain a controversial
topic [
[1]
] despite an increasing number of US states legalizing it [
[2]
] and the growing acceptance of it socially [
[3]
] and even within some physicians in the medical community [
[4]
]. Because of federal laws, studying cannabis in randomized controlled trials remains
a monumental challenge [
[5]
]. Meanwhile cannabis use, much by patients seeking symptomatic relief of their symptoms,
is widespread. This has led to the acknowledgement and subsequent policy statement
by the American College of Emergency Physicians (ACEP) to recommend rescheduling cannabis
so that it can be appropriately studied [
[6]
].- Medical cannabis
Ann. Emerg. Med. 2019; 74 (e93)https://doi.org/10.1016/j.annemergmed.2019.07.034
Keywords
To read this article in full you will need to make a payment
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D; use, select 'Corporate R&D; Professionals'
Subscribe:
Subscribe to The American Journal of Emergency MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- A history of the US medical cannabis movement and its importance to pediatricians: science versus politics in medicine’s greatest catch-22.Clin. Pediatr. (Phila). 2019; 58: 1473-1477https://doi.org/10.1177/0009922819875550
- State medical marijuana laws.2020 (Accessed May 3, 2020)
- A history of the Society of Cannabis Clinicians and its contributions and impact on the US medical cannabis movement.Int J Drug Policy. 2020; 79: 102749https://doi.org/10.1016/j.drugpo.2020.102749
- The practical knowledge, experience and beliefs of US emergency medicine physicians regarding medical cannabis: a national survey.Am. J. Emerg. Med. 2020; S0735-6757: 30071https://doi.org/10.1016/j.ajem.2020.01.059
- The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. Washington, DC.The National Academies Press, 2017https://doi.org/10.17226/24625
- Ann. Emerg. Med. 2019; 74 (e93)https://doi.org/10.1016/j.annemergmed.2019.07.034
- Cannabinoids in the management of acute pain: A systematic review and meta-analysis.Cannabis Cannabinoid Res. 2020; ([in press])https://doi.org/10.1089/can.2019.0079
- The use of cannabis for headache disorders.Cannabis Cannabinoid Res. 2017; 2: 61-71https://doi.org/10.1089/can.2016.0033
- A history of the US medical cannabis movement and its importance to pediatricians: science versus politics in medicine’s greatest catch-22.Clin. Pediatr. (Phila). 2019; 58: 1473-1477https://doi.org/10.1177/0009922819875550
- Prenatal marijuana exposure and neonatal outcomes in Jamaica: an ethnographic study.Pediatrics. 1994; 93: 254-260
- Association between self-reported prenatal cannabis use and maternal, perinatal, and neonatal outcomes.JAMA. 2019 Jul 9; 322 (Published online 2019 Jun 18): 145-152
- FDA approves first drug comprised of an active ingredient derived from marijuana to treat rare, severe forms of epilepsy. U.S. Food and Drug Administration. Silver Spring (MD), 2018 June 25 (Accessed June 21, 2020 at)
Article Info
Publication History
Published online: July 09, 2020
Accepted:
July 1,
2020
Received:
June 27,
2020
Publication stage
In Press Journal Pre-ProofIdentification
Copyright
© 2020 Elsevier Inc. All rights reserved.
